Lista de obras -

A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD.

artículo científico publicado en 2017

Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis

scientific article published on 15 November 2018

Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality

artículo científico publicado en 2018

Burden of Primary Biliary Cholangitis Among Inpatient Population in the United States

artículo científico publicado en 2019

Changing Trends in Etiology- and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States

artículo científico publicado en 2019

Chronic Hepatitis B Is Associated with Higher Inpatient Resource Utilization and Mortality Versus Chronic Hepatitis C.

artículo científico publicado en 2016

Chronic Kidney Disease is Independently Associated with Increased Mortality in Patients with Non-alcoholic Fatty Liver Disease

article

Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices

artículo científico publicado en 2020

Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH).

artículo científico publicado en 2017

Cytokine balance is restored as patient-reported outcomes improve in patients recovering from chronic hepatitis C

scientific article published on 03 May 2019

Development and Validation of a Primary Sclerosing Cholangitis-Specific Patient-Reported Outcomes Instrument: The PSC PRO.

artículo científico publicado en 2017

Development and validation of a hepatitis B-specific health-related quality of life instrument: CLDQ-HBV

scientific article published on 11 December 2020

Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis.

artículo científico publicado en 2017

Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe

artículo científico publicado en 2018

Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France.

artículo científico publicado en 2017

Disparities in Liver Transplantation Resulting From Variations in Regional Donor Supply and Multiple Listing Practices

artículo científico publicado en 2016

Disparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016

article

Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.

artículo científico publicado en 2019

Editorial: a diabetologist's perspective on the diagnosis and monitoring of NAFLD-Authors' reply

artículo científico publicado en 2020

Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection-Author's reply.

artículo científico publicado en 2018

Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.

artículo científico publicado en 2017

Epidemiology of chronic liver diseases in the USA in the past three decades

artículo científico publicado en 2019

Equitable Access to All-Oral Direct-Acting Antiviral Therapy is a Mandatory Step to Achieve Global Hepatitis C Virus Eradication.

artículo científico publicado en 2017

Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes

artículo científico publicado en 2020

Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

artículo científico publicado en 2019

Hospice care in Medicare patients with primary liver cancer: the impact on resource utilisation and mortality

artículo científico publicado en 2018

Hypothetical treatment of patients with non-alcoholic steatohepatitis: Potential impact on important clinical outcomes

scientific article published on 25 November 2019

Impact of Nonmalignant Portal Vein Thrombosis in Transplant Recipients With Nonalcoholic Steatohepatitis

artículo científico publicado en 2019

Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia

artículo científico publicado en 2017

Improved Outcomes in HCV Patients Following Liver Transplantation During the Era of Direct-Acting Antiviral Agents.

artículo científico publicado en 2017

Improvement of Hepatic Fibrosis and Patient-Reported Outcomes in Non-Alcoholic Steatohepatitis Treated with Selonsertib

artículo científico publicado en 2018

In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered

artículo científico publicado en 2017

Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients with Primary Biliary Cholangitis

artículo científico publicado en 2018

Increased cancer rates in patients with chronic hepatitis C

scientific article published on 22 December 2019

Letter: the use of Fibrosis-4 score in primary care and diabetology practices-Occam's razor applied to advanced fibrosis screening. Authors' reply

artículo científico publicado en 2020

Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis

artículo científico publicado en 2022

Long-term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States

artículo científico publicado en 2017

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

artículo científico

Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States

artículo científico publicado en 2019

Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease

scientific article published on 06 June 2019

Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities

scientific article published on 19 May 2020

Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States

artículo científico publicado en 2020

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation.

artículo científico publicado en 2017

Nonalcoholic fatty liver disease: Reporting histologic findings in clinical practice

artículo científico publicado en 2020

Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease.

artículo científico publicado en 2017

Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients

scientific article published on 27 August 2019

Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication

artículo científico publicado en 2019

Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease

artículo científico publicado en 2021

Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH).

artículo científico publicado en 2018

Predictors of Nonalcoholic Steatohepatitis and Significant Fibrosis in Non-Obese Nonalcoholic Fatty Liver Disease

article

Prevalence, mortality and healthcare utilization among Medicare beneficiaries with Hepatitis C in Haemodialysis units

scientific article published on 02 August 2019

Quality of Life in Adolescents with Hepatitis C Treated with Sofosbuvir and Ribavirin

artículo científico publicado en 2017

Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016

artículo científico publicado en 2019

Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network

artículo científico publicado en 2018

Reply

Response to the letter: Hepatitis C screening in opioid epidemics in the United States and societal perspectives.

artículo científico publicado en 2018

Rising Rate of Liver Transplantation in the Baby Boomer Generation with Non-alcoholic Steatohepatitis in the United States

artículo científico publicado en 2017

Securing sustainable funding for viral hepatitis elimination plans

scientific article published on 05 December 2019

Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection

scholarly article by Zobair M. Younossi published in July 2018

Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.

artículo científico publicado en 2017

Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia

artículo científico publicado en 2019

The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases.

artículo científico

The Effect of Interferon-Free Regimens on Health-Related Quality of Life in East Asian Patients with Chronic Hepatitis C.

artículo científico publicado en 2017

The Efficacy of New Anti-Viral Regimens for Hepatitis C Infection: Evidence from A Systematic Review

artículo científico publicado en 2017

The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007-2017

artículo científico publicado en 2020

The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease

artículo científico publicado en 2018

The epidemiology of nonalcoholic steatohepatitis

scientific article published on 20 April 2018

The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease

artículo científico publicado en 2019

Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan.

artículo científico publicado en 2018

Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States

artículo científico publicado en 2017

Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014

scientific article published on 04 June 2019

Underutilization of Living Donor Liver Transplantation in the United States: Bias against MELD 20 and Higher

scientific article published on 25 September 2016

Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C

artículo científico publicado en 2018

Lista de obras de

A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD.

Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis

Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality

Burden of Primary Biliary Cholangitis Among Inpatient Population in the United States

Changing Trends in Etiology- and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States

Chronic Hepatitis B Is Associated with Higher Inpatient Resource Utilization and Mortality Versus Chronic Hepatitis C.

Chronic Kidney Disease is Independently Associated with Increased Mortality in Patients with Non-alcoholic Fatty Liver Disease

Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices

Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH).

Cytokine balance is restored as patient-reported outcomes improve in patients recovering from chronic hepatitis C

Development and Validation of a Primary Sclerosing Cholangitis-Specific Patient-Reported Outcomes Instrument: The PSC PRO.

Development and validation of a hepatitis B-specific health-related quality of life instrument: CLDQ-HBV

Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis.

Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe

Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France.

Disparities in Liver Transplantation Resulting From Variations in Regional Donor Supply and Multiple Listing Practices

Disparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016

Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.

Editorial: a diabetologist's perspective on the diagnosis and monitoring of NAFLD-Authors' reply

Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection-Author's reply.

Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.

Epidemiology of chronic liver diseases in the USA in the past three decades

Equitable Access to All-Oral Direct-Acting Antiviral Therapy is a Mandatory Step to Achieve Global Hepatitis C Virus Eradication.

Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes

Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Hospice care in Medicare patients with primary liver cancer: the impact on resource utilisation and mortality

Hypothetical treatment of patients with non-alcoholic steatohepatitis: Potential impact on important clinical outcomes

Impact of Nonmalignant Portal Vein Thrombosis in Transplant Recipients With Nonalcoholic Steatohepatitis

Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia

Improved Outcomes in HCV Patients Following Liver Transplantation During the Era of Direct-Acting Antiviral Agents.

Improvement of Hepatic Fibrosis and Patient-Reported Outcomes in Non-Alcoholic Steatohepatitis Treated with Selonsertib

In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered

Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients with Primary Biliary Cholangitis

Increased cancer rates in patients with chronic hepatitis C

Letter: the use of Fibrosis-4 score in primary care and diabetology practices-Occam's razor applied to advanced fibrosis screening. Authors' reply

Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis

Long-term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States

Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease

Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities

Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation.

Nonalcoholic fatty liver disease: Reporting histologic findings in clinical practice

Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease.

Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients

Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication

Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease

Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH).

Predictors of Nonalcoholic Steatohepatitis and Significant Fibrosis in Non-Obese Nonalcoholic Fatty Liver Disease

Prevalence, mortality and healthcare utilization among Medicare beneficiaries with Hepatitis C in Haemodialysis units

Quality of Life in Adolescents with Hepatitis C Treated with Sofosbuvir and Ribavirin

Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016

Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network

Reply

Response to the letter: Hepatitis C screening in opioid epidemics in the United States and societal perspectives.

Rising Rate of Liver Transplantation in the Baby Boomer Generation with Non-alcoholic Steatohepatitis in the United States

Securing sustainable funding for viral hepatitis elimination plans

Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection

Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.

Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia

The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases.

The Effect of Interferon-Free Regimens on Health-Related Quality of Life in East Asian Patients with Chronic Hepatitis C.

The Efficacy of New Anti-Viral Regimens for Hepatitis C Infection: Evidence from A Systematic Review

The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007-2017

The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease

The epidemiology of nonalcoholic steatohepatitis

The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease

Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan.

Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States

Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014

Underutilization of Living Donor Liver Transplantation in the United States: Bias against MELD 20 and Higher

Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C